ICCM Stock On Track For Best Day In Nearly 5 Years — What’s Driving The 200% Rally?

IceCure reported a 70% increase in its active U.S. commercial install base of ProSense systems.

• ProSense was granted FDA marketing authorization in October 2025.
• The CEO hinted that the firm sees further commercial opportunities for the system. 
• According to data from Koyfin, all three analysts covering ICCM rate it ‘Buy’ or higher.

Shares of IceCure Medical Ltd. (ICCM) exploded over 200% on Wednesday, fueled by positive news of accelerating adoption of the company’s ProSense system in the U.S.

IceCure reported a 70% increase in its active U.S. commercial install base of ProSense systems used for breast cancer treatment since the FDA granted marketing authorization in October 2025.

The stock is now on track for its best day since August 2021, if gains hold.

ICCM Execs Weigh In

IceCure said it continues to add new ProSense systems at clinics and hospitals across the country. The systems are already being used for procedures in major cities, including Los Angeles, New York, Atlanta, Dallas, Detroit, Philadelphia, Phoenix, Memphis and many other communities.

“With growing physician interest, expanding clinical acceptance, and increased patient awareness, we believe we remain in the early stages of a significant commercial opportunity for breast cancer cryoablation in the U.S. We are focused on continuing to expand our installed base, supporting physicians with training and education and increasing access to ProSense for eligible patients,” IceCure CEO Eyal Shamir said.

What Is ProSense?

ProSense is a minimally invasive system that destroys tumors by freezing them with liquid nitrogen. It offers an alternative to traditional surgery for removing tumors, often with faster recovery, less pain, and fewer complications. Procedures can typically be done in an office setting.

IceCure’s ProSense system is currently the first and only medical device specifically authorized by the FDA for the local treatment of low-risk breast cancer in women aged 70 and older, combined with standard hormone therapy, including patients who may not be suitable for surgery.

How Did ICCM Retail Traders React?

On Stocktwits, retail sentiment toward ICCM stock surged from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume climbed from ‘normal’ to ‘extremely high.’

A Stocktwits user said that they see way more upside for the stock.

Another termed the stock an incredible investment opportunity.

According to data from Koyfin, all three analysts covering ICCM rate it ‘Buy’ or higher. The stock has an average price target of $44.50, representing a potential upside of nearly 2000% from the stock's last closing price.

ICCM stock has lost about 67% this year after reporting persistent first-quarter losses. 

For updates and corrections, email newsroom[at]stocktwits[dot]com.<